Biotech Stocks; Medicago (TSX: MDG ) holds official groundbreaking ceremony for its U.S. commercial grade vaccine facility.
- Appoints Vice President of U.S. Operations -
RALEIGH, NC and QUEBEC CITY, Oct. 1 (http://www.investorideas.com/ biotech stocks blog ) - Medicago U.S.A. Inc., a wholly owned subsidiary of Medicago Inc. (TSX: MDG ), a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that company executives, along with U.S. Senator Kay Hagan (D-NC) and U.S. Congressman David Price (D-NC), are holding an official groundbreaking ceremony this morning for its U.S. plant-based commercial grade vaccine facility in Research Triangle Park, North Carolina. Medicago U.S.A. also announced the appointment of Mike Wanner as Vice President of U.S. Operations.
With today's groundbreaking ceremony, Medicago U.S.A. officially commenced the construction of its cGMP facility in Research Triangle Park (RTP), North Carolina. This VLP plant-based vaccine facility will include a fully automated greenhouse and a state of the art extraction and purification unit. The facility is targeted to produce 10 million doses of pandemic influenza vaccine per month. On an annual basis, the facility would have production capacity of 40 million doses of seasonal Influenza vaccine or 120 million doses of pandemic influenza vaccine.
"Thanks to the efforts and experience of our partners Alexandria Real Estate Equities and BE&K Building Group as well as our employees at Medicago, we are confident that this fast-track project will be delivered on time," said Andy Sheldon, President and CEO of Medicago. "North Carolina and RTP is a great place to build our business due to the excellent workforce, training programs and quality of life."
"We are very pleased to be working with Alexandria Real Estate Equities and with Medicago who is bringing this unique, rapid and cost-effective vaccine technology to North Carolina and to the Research Triangle Park," stated Joseph M. Raimondi, Project Executive of BE&K Building Group.
Mr. Wanner joins Medicago U.S.A. as Vice President of U.S. Operations and will lead the Company's U.S. expansion efforts. He was previously President and CEO of Abeome, a biotechnology company developing therapeutic and diagnostic monoclonal antibodies. Mr. Wanner served for over 11 years as CFO for Merial and Rhone Merieux, Inc. (RMI), one of the world's leading animal health companies, where he was involved in the construction and management of a large scale vaccine production facility in the U.S.
"Mike is a key addition to our senior management team. He brings tremendous experience in the vaccine industry and his hands on knowledge in the construction and management of a large-scale U.S. vaccine production facility will have immediate benefits in our U.S expansion efforts," stated Mr. Sheldon. "This expansion is a key part of our development plan for both our pandemic and seasonal influenza products as we will now have a U.S. commercial facility ready to participate in the $7B pandemic and seasonal influenza markets. Moreover, our U.S. facility will strengthen our relationships with key stakeholders in the U.S. and will provide us with enhanced access to the various grant programs for additional funding awards."
Members of the media are invited to attend the official ground breaking ceremony
When: Friday, October 1st at 10:00am Where: 7 Triangle Drive, Research Triangle Park, NC 27709
About Medicago
Medicago is committed to providing highly effective and affordable vaccines based on proprietary Virus-Like Particle (VLP) and manufacturing technologies. Medicago is developing VLP vaccines to protect against pandemic and seasonal influenza using a transient expression system which produces recombinant vaccine antigens in non-transgenic plants. Their lead vaccine candidate, H5N1, has successfully completed a PI clinical trial and will be entering a PII clinical trial in 2010. Medicago's technology has potential to offer advantages of speed and cost over competitive technologies. It could deliver a vaccine for testing in about a month after the identification and reception of genetic sequences from a pandemic strain. This production time frame has the potential to allow vaccination of the population before the first wave of a pandemic strikes and to supply large volumes of vaccine antigens to the world market. Additional information about Medicago is available at http://www.medicago.com/.
Forward Looking Statements
This news release includes certain forward-looking statements that are based upon current expectations, which involve risks and uncertainties associated with Medicago's business and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "anticipate", "believe", "plan", "estimate", "expect", "intend", and similar expressions to the extent they relate to Medicago or its management. The forward-looking statements are not historical facts, but reflect Medicago's current expectations regarding future results or events. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations, including the matters discussed under "Risks Factors and Uncertainties" in Medicago's Annual Information Form filed on March 24, 2010 with the regulatory authorities. Medicago assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.
For further information
Medicago, Inc., Andy Sheldon, President and CEO, (418) 658-9393
Medicago Inc., Christina Cameron, Investor Relations Manager, (418) 658-9393 x156
More Investorideas Biotech Stocks info wwww.BiotechIndustryStocks.com - A Leading Global Investor Website for Biotech Industry Stocks, Biotech, Pharma and Industry News and Biotech Investor Research Tools including a Biotech Stocks Directory
Biotech Companies - become a biotech showcase stock on www.investorideas.com and www.biotechindustrystocks.com for as little as $1000 month !
Friday, October 1, 2010
Thursday, September 30, 2010
Biotech Stocks; Meridian Bioscience (NASDAQ:VIVO) Receives Canadian License for illumigene™ C. difficile
Biotech Stocks; Meridian Bioscience (NASDAQ:VIVO) Receives Canadian License for illumigene™ C. difficile
CINCINNATI--(http://www.investorideas.com/ biotech stocks blog )--Meridian Bioscience, Inc., (NASDAQ:VIVO) today announced that it has received an approved medical device license from Health Canada for its new molecular amplification assay, illumigene C. difficile. Clostridium difficile is a bacterium that can cause diarrhea and, in severe cases, a life-threatening inflammation of the colon. The illumigene molecular amplification assay detects the presence of the toxin producing region from the C. difficile DNA, and provides highly accurate results in under an hour. Meridian, a leading manufacturer of rapid immunoassay C. difficile tests, expands its existing portfolio with this new, simpler molecular assay. Having received this license, the Company will be uniquely positioned in the Canadian market to provide a full line of C. difficile testing solutions that meet the needs of its clinical lab customers.
The new illumigene C. difficile molecular diagnostic system provides high levels of sensitivity for diagnosing this serious, infectious disease. Its simple workflow requires minimal hands-on time per sample. The product has been recently launched successfully in the U.S. as well as in Australia, Taiwan and most European markets.
Jack Kraeutler, Chief Executive Officer, commented, "Toxin producing C. difficile infections, especially in hospitalized patients, can have especially devastating consequences if not diagnosed and treated quickly. Because disease symptoms of C. difficile infection can strike patients at any hour of the day or night, Meridian designed illumigene C. difficile to enable real-time molecular testing in any lab at any time. With minimal hands-on time and virtually no capital expense, illumigene gives any infectious disease lab access to a convenient and powerful DNA amplification platform.”
Forward Looking Statements
The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as "estimates", "anticipates", "projects", "plans", "seeks", "may", "will", "expects", "intends", "believes", "should" and similar expressions or the negative versions thereof and which also may be identified by their context. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. The Company assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following: Meridian's continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian's competition. While Meridian has introduced a number of internally developed products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which our customers operate, as well as adverse trends in buying patterns from customers can change expected results. Costs and difficulties in complying with laws and regulations administered by the United States Food and Drug Administration can result in unanticipated expenses and delays and interruptions to the sale of new and existing products. Changes in the relative strength or weakness of the U.S. dollar can also change expected results. One of Meridian's main growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses successfully integrated into Meridian's operations. The Company cannot predict the possible effects of potential healthcare reform in the United States and similar initiatives in other countries on its results of operations. In addition to the factors described in this paragraph, Part I, Item 1A Risk Factors of our Form 10-K contains a list and description of uncertainties, risks and other matters that may affect the Company.
Meridian is a fully integrated life science company that manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Utilizing a variety of methods, these products and diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral and respiratory infections. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company's products are designed to enhance patient well-being while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, serology, parasitology and fungal disease diagnosis. In addition, Meridian is a supplier of rare reagents, specialty biologicals and related technologies used by biopharmaceutical companies engaged in research for new drugs and vaccines. The Company markets its products and technologies to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers and biotech companies in more than 60 countries around the world. The Company’s shares are traded through NASDAQ’s Global Select Market, symbol VIVO. Meridian's website address is www.meridianbioscience.com.
Contacts
Meridian Bioscience, Inc.
John A. Kraeutler, Chief Executive Officer, 513-271-3700
More Investorideas Biotech Stocks info wwww.BiotechIndustryStocks.com
- A Leading Global Investor Website for Biotech Industry Stocks, Biotech, Pharma and Industry News and Biotech Investor Research Tools including a Biotech Stocks Directory
Biotech Companies - become a biotech showcase stock on http://www.investorideas.com/ and http://www.biotechindustrystocks.com/
for as little as $1000 month !
CINCINNATI--(http://www.investorideas.com/ biotech stocks blog )--Meridian Bioscience, Inc., (NASDAQ:VIVO) today announced that it has received an approved medical device license from Health Canada for its new molecular amplification assay, illumigene C. difficile. Clostridium difficile is a bacterium that can cause diarrhea and, in severe cases, a life-threatening inflammation of the colon. The illumigene molecular amplification assay detects the presence of the toxin producing region from the C. difficile DNA, and provides highly accurate results in under an hour. Meridian, a leading manufacturer of rapid immunoassay C. difficile tests, expands its existing portfolio with this new, simpler molecular assay. Having received this license, the Company will be uniquely positioned in the Canadian market to provide a full line of C. difficile testing solutions that meet the needs of its clinical lab customers.
The new illumigene C. difficile molecular diagnostic system provides high levels of sensitivity for diagnosing this serious, infectious disease. Its simple workflow requires minimal hands-on time per sample. The product has been recently launched successfully in the U.S. as well as in Australia, Taiwan and most European markets.
Jack Kraeutler, Chief Executive Officer, commented, "Toxin producing C. difficile infections, especially in hospitalized patients, can have especially devastating consequences if not diagnosed and treated quickly. Because disease symptoms of C. difficile infection can strike patients at any hour of the day or night, Meridian designed illumigene C. difficile to enable real-time molecular testing in any lab at any time. With minimal hands-on time and virtually no capital expense, illumigene gives any infectious disease lab access to a convenient and powerful DNA amplification platform.”
Forward Looking Statements
The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as "estimates", "anticipates", "projects", "plans", "seeks", "may", "will", "expects", "intends", "believes", "should" and similar expressions or the negative versions thereof and which also may be identified by their context. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. The Company assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following: Meridian's continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian's competition. While Meridian has introduced a number of internally developed products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which our customers operate, as well as adverse trends in buying patterns from customers can change expected results. Costs and difficulties in complying with laws and regulations administered by the United States Food and Drug Administration can result in unanticipated expenses and delays and interruptions to the sale of new and existing products. Changes in the relative strength or weakness of the U.S. dollar can also change expected results. One of Meridian's main growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses successfully integrated into Meridian's operations. The Company cannot predict the possible effects of potential healthcare reform in the United States and similar initiatives in other countries on its results of operations. In addition to the factors described in this paragraph, Part I, Item 1A Risk Factors of our Form 10-K contains a list and description of uncertainties, risks and other matters that may affect the Company.
Meridian is a fully integrated life science company that manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Utilizing a variety of methods, these products and diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral and respiratory infections. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company's products are designed to enhance patient well-being while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, serology, parasitology and fungal disease diagnosis. In addition, Meridian is a supplier of rare reagents, specialty biologicals and related technologies used by biopharmaceutical companies engaged in research for new drugs and vaccines. The Company markets its products and technologies to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers and biotech companies in more than 60 countries around the world. The Company’s shares are traded through NASDAQ’s Global Select Market, symbol VIVO. Meridian's website address is www.meridianbioscience.com.
Contacts
Meridian Bioscience, Inc.
John A. Kraeutler, Chief Executive Officer, 513-271-3700
More Investorideas Biotech Stocks info wwww.BiotechIndustryStocks.com
- A Leading Global Investor Website for Biotech Industry Stocks, Biotech, Pharma and Industry News and Biotech Investor Research Tools including a Biotech Stocks Directory
Biotech Companies - become a biotech showcase stock on http://www.investorideas.com/ and http://www.biotechindustrystocks.com/
for as little as $1000 month !
TSX Biotech Stocks; Kane Biotech (TSX VENTURE:KNE), Announces Grant of Options
TSX Biotech Stocks; Kane Biotech (TSX VENTURE:KNE), Announces Grant of Options
(http://www.investorideas.com/ biotech stocks blog )
Kane Biotech Inc. (TSX VENTURE:KNE), a biotechnology company engaged in the development and commercialization of products that prevent and disperse microbial biofilms, announces today that it has granted an aggregate of 215,000 stock options at an exercise price of $0.10 per common share, to four independent directors of the Company. The options are set to expire five years from the date of grant and are subject to TSX Venture Exchange acceptance and the terms of Kane Biotech's stock option plan. In accordance with securities regulatory requirements, any shares issued pursuant to the exercise of such options will be subject to a resale restriction for a period of four months from the date of the grant.
About Kane Biotech Inc.
Kane Biotech is a biotechnology company engaged in the development and commercialization of products to prevent and disperse biofilms. Biofilms develop when bacteria, and other microorganisms, form a protective matrix that acts as a shield against attack. When in a biofilm, bacteria become highly resistant to antibiotics, biocides, disinfectants, high temperatures and host immune responses. This resiliency contributes to human health problems such as recurrent urinary tract infections, medical device associated infections and tooth decay.
Kane Biotech uses a patent protected technology based on molecular mechanisms of biofilm formation and methods for finding compounds that inhibit or disrupt biofilms. The Company has evidence that this technology has potential to significantly improve the ability to prevent and/or destroy biofilms in several medical and industrial applications.
Caution Regarding Forward-Looking Information
Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, "forward-looking statements"). These forward-looking statements relate to, among other things, our objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, including, without limitation, our anticipated future operating results, and can, in some cases, be identified by the use of words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.
These statements reflect management's current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: Kane's early stage of development, lack of product revenues and history of operating losses, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, supply of raw materials, income tax matters, management of growth, partnerships for development and commercialization of technology, effects of insurers' willingness to pay for products, system failures, dependence on key personnel, foreign currency risk, risks related to regulatory matters and risks related to intellectual property and other risks detailed from time to time in Kane's filings with Canadian securities regulatory authorities, as well as Kane's ability to anticipate and manage the risks associated with the foregoing. Kane cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on Kane's forward-looking statements to make decisions with respect to Kane, investors and others should carefully consider the foregoing factors and other uncertainties and potential events.
These risks and uncertainties should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, Kane cannot provide assurance that actual results will be consistent with these forward-looking statements. Kane undertakes no obligation to update or revise any forward-looking statement.
The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.
For more information, please contact
Kane Biotech Inc.
Albert D. Friesen
Chairman
204-928-7205
204-453-1314 (FAX)
ir@kanebiotech.com
www.kanebiotech.com
More Investorideas Biotech Stocks info wwww.BiotechIndustryStocks.com
- A Leading Global Investor Website for Biotech Industry Stocks, Biotech, Pharma and Industry News and Biotech Investor Research Tools including a Biotech Stocks Directory
Biotech Companies - become a biotech showcase stock on www.investorideas.com and www.biotechindustrystocks.com for as little as $1000 month !
(http://www.investorideas.com/ biotech stocks blog )
Kane Biotech Inc. (TSX VENTURE:KNE), a biotechnology company engaged in the development and commercialization of products that prevent and disperse microbial biofilms, announces today that it has granted an aggregate of 215,000 stock options at an exercise price of $0.10 per common share, to four independent directors of the Company. The options are set to expire five years from the date of grant and are subject to TSX Venture Exchange acceptance and the terms of Kane Biotech's stock option plan. In accordance with securities regulatory requirements, any shares issued pursuant to the exercise of such options will be subject to a resale restriction for a period of four months from the date of the grant.
About Kane Biotech Inc.
Kane Biotech is a biotechnology company engaged in the development and commercialization of products to prevent and disperse biofilms. Biofilms develop when bacteria, and other microorganisms, form a protective matrix that acts as a shield against attack. When in a biofilm, bacteria become highly resistant to antibiotics, biocides, disinfectants, high temperatures and host immune responses. This resiliency contributes to human health problems such as recurrent urinary tract infections, medical device associated infections and tooth decay.
Kane Biotech uses a patent protected technology based on molecular mechanisms of biofilm formation and methods for finding compounds that inhibit or disrupt biofilms. The Company has evidence that this technology has potential to significantly improve the ability to prevent and/or destroy biofilms in several medical and industrial applications.
Caution Regarding Forward-Looking Information
Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, "forward-looking statements"). These forward-looking statements relate to, among other things, our objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, including, without limitation, our anticipated future operating results, and can, in some cases, be identified by the use of words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.
These statements reflect management's current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: Kane's early stage of development, lack of product revenues and history of operating losses, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, supply of raw materials, income tax matters, management of growth, partnerships for development and commercialization of technology, effects of insurers' willingness to pay for products, system failures, dependence on key personnel, foreign currency risk, risks related to regulatory matters and risks related to intellectual property and other risks detailed from time to time in Kane's filings with Canadian securities regulatory authorities, as well as Kane's ability to anticipate and manage the risks associated with the foregoing. Kane cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on Kane's forward-looking statements to make decisions with respect to Kane, investors and others should carefully consider the foregoing factors and other uncertainties and potential events.
These risks and uncertainties should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, Kane cannot provide assurance that actual results will be consistent with these forward-looking statements. Kane undertakes no obligation to update or revise any forward-looking statement.
The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.
For more information, please contact
Kane Biotech Inc.
Albert D. Friesen
Chairman
204-928-7205
204-453-1314 (FAX)
ir@kanebiotech.com
www.kanebiotech.com
More Investorideas Biotech Stocks info wwww.BiotechIndustryStocks.com
- A Leading Global Investor Website for Biotech Industry Stocks, Biotech, Pharma and Industry News and Biotech Investor Research Tools including a Biotech Stocks Directory
Biotech Companies - become a biotech showcase stock on www.investorideas.com and www.biotechindustrystocks.com for as little as $1000 month !
Wednesday, September 29, 2010
Investorideas.com - OTC Trading Alert; Sectors Include Biotech and Gold Stocks ($1.00-$2.00): (ISCO, NNVC, MNEAF, AMOK)
Investorideas.com - OTC Trading Alert; Sectors Include Biotech and Gold Stocks ($1.00-$2.00): (ISCO, NNVC, MNEAF, AMOK)
Note to Editors: The Following Is an Investment Opinion Being Issued by OTC VOLUME LEADERS
Category: Investment, Financial
Subscribe to Investor Ideas Newswire
Visit this company: http://www.otcvolumeleaders.com/
Point Roberts, WA (Investorideas.com Newswire) September 29, 2010 - OTC VOLUME LEADERS reports on the most active trading stocks on the OTCBB. OTC Volume leaders ($1.00-$2.00) include Minera Andes Inc. (OTCBB: MNEAF), (OTCBB: AMOK), International Stem Cell Corporation (OTCBB: ISCO), and NanoViricides, Inc. (OTCBB: NNVC).
Sign up at OTC Volume leaders and get access to info on hundreds of the most active OTCBB companies by clicking the sign up link belowhttp://bit.ly/otcvolumeleaders
OTC/Market Commentary:
Biotech Stocks:
One of the OTCBB volume leaders; Recent News: "International Stem Cell Corporation www.internationalstemcell.com, announced today that its oocyte collection and activation protocol has received the approval of an Institutional Review Board (IRB). IRB review and approval is a Federal requirement for all studies enrolling human subjects, and ensures appropriate subject safety and monitoring to protect subjects from unnecessary medical risks. "Obtaining IRB approval for our oocyte collection and activation protocol is a major step forward towards the goal of building a viable bank of human parthenogenetic stem cells," said Dr. Simon Craw, Vice President of ISCO."
Full Article: http://finance.yahoo.com/news/International-Stem-Cell-bw-3037073202.html?x=0&.v=1
One of the OTCBB volume leaders; Recent News: "NanoViricides, Inc. (the "Company"), announced today that Anil Diwan, PhD, President of the Company has been invited to participate in a panel discussion on nanomedicines development at the NanoBusiness2010. This event is taking place today at 2pm CDT at the 9th annual NanoBusiness Conference, held at the McCormick Place in Chicago, IL."
Full Article: http://finance.yahoo.com/news/NanoViricides-Inc-President-bw-3964763916.html?x=0&.v=1
(OTCBB: AQUM)
Market Snapshot: (at time of release)
Dow 10,859.61 +1.47 +0.01%
Nasdaq 2,380.78 +1.19 +0.05%
S&P 500 1,147.76 +0.06 +0.01%
10 Yr Bond(%) 2.5080% +0.5200
Oil 77.92 +1.74 +2.28%
Gold 1,309.80 +3.20 +0.24%
OTCBB Investors: Take the few minutes to register with us at To sign up for free Newsletter http://bit.ly/otcvolumeleaders and get access to info on hundreds of the most active OTCBB companies and keep up to date with developments of the companies.
OTC VOLUME LEADERS provides investors with daily market updates showcasing the most actively traded OTCBB Companies. We strive to provide you with the most up-to-date market information and activity by searching through hundreds of OTCBB companies in order to provide you information on the best of these companies. The goal is to continually find tomorrow’s market leading companies, today!
OTCVolumeleaders.com has not been compensated by any of the above mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks.
Please view the full disclaimer: http://www.otcvolumeleaders.com/Source http://www.otcvolumeleaders.com/Follow OTC Volume Leaders on Twitter.com http://twitter.com/OTCVolumeLeader
* Attention Investors in British Columbia Canada: Do not subscribe to any OTC stocks not currently filing with Sedar in BC and BC Securities
Visit the OTC showcase profile at Investorideas.com Request News and Info on OTC Investors - Get OTC stock quotes from http://www.otcmarkets.com/ Disclosure, Disclaimer/ OTC is a paid advertising client on Investorideas.com.
More Info:
Published at http://www.investorideas.com/ - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Note to Editors: The Following Is an Investment Opinion Being Issued by OTC VOLUME LEADERS
Category: Investment, Financial
Subscribe to Investor Ideas Newswire
Visit this company: http://www.otcvolumeleaders.com/
Point Roberts, WA (Investorideas.com Newswire) September 29, 2010 - OTC VOLUME LEADERS reports on the most active trading stocks on the OTCBB. OTC Volume leaders ($1.00-$2.00) include Minera Andes Inc. (OTCBB: MNEAF), (OTCBB: AMOK), International Stem Cell Corporation (OTCBB: ISCO), and NanoViricides, Inc. (OTCBB: NNVC).
Sign up at OTC Volume leaders and get access to info on hundreds of the most active OTCBB companies by clicking the sign up link belowhttp://bit.ly/otcvolumeleaders
OTC/Market Commentary:
Biotech Stocks:
One of the OTCBB volume leaders; Recent News: "International Stem Cell Corporation www.internationalstemcell.com, announced today that its oocyte collection and activation protocol has received the approval of an Institutional Review Board (IRB). IRB review and approval is a Federal requirement for all studies enrolling human subjects, and ensures appropriate subject safety and monitoring to protect subjects from unnecessary medical risks. "Obtaining IRB approval for our oocyte collection and activation protocol is a major step forward towards the goal of building a viable bank of human parthenogenetic stem cells," said Dr. Simon Craw, Vice President of ISCO."
Full Article: http://finance.yahoo.com/news/International-Stem-Cell-bw-3037073202.html?x=0&.v=1
One of the OTCBB volume leaders; Recent News: "NanoViricides, Inc. (the "Company"), announced today that Anil Diwan, PhD, President of the Company has been invited to participate in a panel discussion on nanomedicines development at the NanoBusiness2010. This event is taking place today at 2pm CDT at the 9th annual NanoBusiness Conference, held at the McCormick Place in Chicago, IL."
Full Article: http://finance.yahoo.com/news/NanoViricides-Inc-President-bw-3964763916.html?x=0&.v=1
(OTCBB: AQUM)
Market Snapshot: (at time of release)
Dow 10,859.61 +1.47 +0.01%
Nasdaq 2,380.78 +1.19 +0.05%
S&P 500 1,147.76 +0.06 +0.01%
10 Yr Bond(%) 2.5080% +0.5200
Oil 77.92 +1.74 +2.28%
Gold 1,309.80 +3.20 +0.24%
OTCBB Investors: Take the few minutes to register with us at To sign up for free Newsletter http://bit.ly/otcvolumeleaders and get access to info on hundreds of the most active OTCBB companies and keep up to date with developments of the companies.
OTC VOLUME LEADERS provides investors with daily market updates showcasing the most actively traded OTCBB Companies. We strive to provide you with the most up-to-date market information and activity by searching through hundreds of OTCBB companies in order to provide you information on the best of these companies. The goal is to continually find tomorrow’s market leading companies, today!
OTCVolumeleaders.com has not been compensated by any of the above mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks.
Please view the full disclaimer: http://www.otcvolumeleaders.com/Source http://www.otcvolumeleaders.com/Follow OTC Volume Leaders on Twitter.com http://twitter.com/OTCVolumeLeader
* Attention Investors in British Columbia Canada: Do not subscribe to any OTC stocks not currently filing with Sedar in BC and BC Securities
Visit the OTC showcase profile at Investorideas.com Request News and Info on OTC Investors - Get OTC stock quotes from http://www.otcmarkets.com/ Disclosure, Disclaimer/ OTC is a paid advertising client on Investorideas.com.
More Info:
Published at http://www.investorideas.com/ - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Investorideas.com - UV Flu Technologies Receives Large UV-400 Air Purifier Order Directly Targeting Residential Marketplace
Investorideas.com - UV Flu Technologies Receives Large UV-400 Air Purifier Order Directly Targeting Residential Marketplace
OTCBB:UVFT
Visit this company: http://www.uvflutech.com/
CENTERVILLE, MA - September 29, 2010 (http://www.investorideas.com/ newswire, http://www.biotechindustrystocks.com/) - UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") is pleased to announce that the company has received an order for 100 UV-400 air purifying units from Semper Fi, a Long Island based distribution company which primarily markets to residential consumers.
The Distributor has advised that they are actively adding representatives to cover sales leads encompassing the Tri-State area. In response, the Company has ensured that an ample quantity of units to satisfy initial sales needs have been priority diverted for immediate shipment to the client.
"This order is significant because our product was principally designed for the commercial marketplace," said Jack Lennon, President of UV Fu Technologies. "Our UV-400 has been laboratory tested and proven to offer highly effective airborne bacteria-killing capabilities that will provide Semper Fi with a product truly superior to anything else currently in the marketplace."
Mr. Lennon continues, "We want to also note that in the residential market we have received feedback from the field where certain individuals have reported a dramatic difference in their respiratory issues in as little as 2-3 hours from starting their UV-400 at home. In the past month alone, we have received testimonials from consumers indicating that individuals with sleep disorders due to snoring have seen significant improvement while operating the unit in their bedroom at night. The Company makes no claims in this area, but is planning to follow up on these reports in order to determine if further study or future development in this area is warranted."
Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.bout UV Flu Technologies, Inc. (OTCBB: UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector. The Company manufactures the ViraTech UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. ViraTech UV-400 is a Class II medical device and is available without a prescription.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Investor Information:Geaux IR Services, Inc.Toll-Free: 1-888-355-8838investors@uvflutech.com
SOURCE: UV Flu Technologies, Inc.
More Info:
Published at http://www.investorideas.com/ - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Connect with Investorideas.com
Publish Your News - Send a release
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
OTCBB:UVFT
Visit this company: http://www.uvflutech.com/
CENTERVILLE, MA - September 29, 2010 (http://www.investorideas.com/ newswire, http://www.biotechindustrystocks.com/) - UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") is pleased to announce that the company has received an order for 100 UV-400 air purifying units from Semper Fi, a Long Island based distribution company which primarily markets to residential consumers.
The Distributor has advised that they are actively adding representatives to cover sales leads encompassing the Tri-State area. In response, the Company has ensured that an ample quantity of units to satisfy initial sales needs have been priority diverted for immediate shipment to the client.
"This order is significant because our product was principally designed for the commercial marketplace," said Jack Lennon, President of UV Fu Technologies. "Our UV-400 has been laboratory tested and proven to offer highly effective airborne bacteria-killing capabilities that will provide Semper Fi with a product truly superior to anything else currently in the marketplace."
Mr. Lennon continues, "We want to also note that in the residential market we have received feedback from the field where certain individuals have reported a dramatic difference in their respiratory issues in as little as 2-3 hours from starting their UV-400 at home. In the past month alone, we have received testimonials from consumers indicating that individuals with sleep disorders due to snoring have seen significant improvement while operating the unit in their bedroom at night. The Company makes no claims in this area, but is planning to follow up on these reports in order to determine if further study or future development in this area is warranted."
Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.bout UV Flu Technologies, Inc. (OTCBB: UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector. The Company manufactures the ViraTech UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. ViraTech UV-400 is a Class II medical device and is available without a prescription.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Investor Information:Geaux IR Services, Inc.Toll-Free: 1-888-355-8838investors@uvflutech.com
SOURCE: UV Flu Technologies, Inc.
More Info:
Published at http://www.investorideas.com/ - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Connect with Investorideas.com
Publish Your News - Send a release
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Tuesday, September 28, 2010
Investorideas.com - OTC Trading Alert; Volume Leader Biotech Stocks: ($0.14-$0.25): (OTCBB: KBLB), (OTCBB: SNGX), (OTCBB: SFMI), (OTCBB: CHTL)
Investorideas.com - OTC Trading Alert; Volume Leader Biotech Stocks: ($0.14-$0.25): (OTCBB: KBLB), (OTCBB: SNGX), (OTCBB: SFMI), (OTCBB: CHTL)
Note to Editors: The Following Is an Investment Opinion Being Issued by OTC VOLUME LEADERS
Category: Investment, Financial
Subscribe to Investor Ideas Newswire
Visit this company: http://www.otcvolumeleaders.com/
Point Roberts, WA (Investorideas.com Newswire) September 28, 2010 - OTC VOLUME LEADERS reports on the most active trading stocks on the OTCBB. OTC Volume leaders ($0.14-$0.25) include Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB), Soligenix, Inc . (OTCBB: SNGX), Silver Falcon Mining, Inc. (OTCBB: SFMI), and China Tel Group Inc. (OTCBB: CHTL).
Sign up for Tomorrows Hot OTC Market Leaders Today!Email:
Sign up at OTC Volume leaders and get access to info on hundreds of the most active OTCBB companies by clicking the sign up link below
http://bit.ly/otcvolumeleaders
OTC/Market Commentary:
Sectors include Biotech Stocks
One of the OTCBB volume leader reports; Soligenix, Inc. (OTCBB: SNGX): "Soligenix, Inc. (Soligenix) is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. Soligenix's lead product, orBec® (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of acute gastrointestinal Graft-versus-Host-Disease (GI GVHD), a common and potentially life-threatening complication of hematopoietic cell transplantation. orBec® is currently the subject of a confirmatory Phase 3 clinical trial for the treatment of acute GI GVHD and an NIH-supported, Phase 2, randomized, double-blind, placebo-controlled trial in the prevention of acute GVHD. Soligenix is also conducting an NIH-supported Phase 1/2 clinical trial of SGX201 in the prevention of acute radiation enteritis. Additionally, Soligenix has a Lipid Polymer Micelle (LPM™) drug delivery technology for the oral delivery of leuprolide for the treatment of prostate cancer and endometriosis.
Through its Biodefense Division, Soligenix is developing biomedical countermeasures pursuant to the Project BioShield Act of 2004. Soligenix's lead biodefense product in development is a recombinant subunit vaccine called RiVax™, which is designed to protect against the lethal effects of exposure to ricin toxin. RiVax™ has been shown to be well tolerated and immunogenic in a Phase 1 clinical trial in normal volunteers. RiVax™ is also the subject of a $9.4 million NIH grant received by the Company supporting development of new heat stable vaccines.
For further information regarding Soligenix, Inc., please visit the Company's website at http://www.soligenix.com/."
Market Snapshot: (at time of release)
Dow 10,851.74 +39.70 +0.37%
Nasdaq 2,374.76 +4.99 +0.21%
S&P 500 1,145.65 +3.49 +0.31%
10 Yr Bond(%) 2.4800% -0.3700
Oil 76.76 +0.24 +0.31%
Gold 1,287.50 -3.40 -0.26%
OTCBB Investors: Take the few minutes to register with us at To sign up for free Newsletter http://bit.ly/otcvolumeleaders and get access to info on hundreds of the most active OTCBB companies and keep up to date with developments of the companies.
OTC VOLUME LEADERS provides investors with daily market updates showcasing the most actively traded OTCBB Companies. We strive to provide you with the most up-to-date market information and activity by searching through hundreds of OTCBB companies in order to provide you information on the best of these companies. The goal is to continually find tomorrow’s market leading companies, today!
OTCVolumeleaders.com has not been compensated by any of the above mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks.
Please view the full disclaimer: http://www.otcvolumeleaders.com/Source http://www.otcvolumeleaders.com/Follow OTC Volume Leaders on Twitter.com http://twitter.com/OTCVolumeLeader
* Attention Investors in British Columbia Canada: Do not subscribe to any OTC stocks not currently filing with Sedar in BC and BC Securities
Visit the OTC showcase profile at Investorideas.com Request News and Info on OTC Investors - Get OTC stock quotes from http://www.otcmarkets.com/ Disclosure, Disclaimer/ OTC is a paid advertising client on Investorideas.com.
More Info:
Published at http://www.investorideas.com/ - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Note to Editors: The Following Is an Investment Opinion Being Issued by OTC VOLUME LEADERS
Category: Investment, Financial
Subscribe to Investor Ideas Newswire
Visit this company: http://www.otcvolumeleaders.com/
Point Roberts, WA (Investorideas.com Newswire) September 28, 2010 - OTC VOLUME LEADERS reports on the most active trading stocks on the OTCBB. OTC Volume leaders ($0.14-$0.25) include Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB), Soligenix, Inc . (OTCBB: SNGX), Silver Falcon Mining, Inc. (OTCBB: SFMI), and China Tel Group Inc. (OTCBB: CHTL).
Sign up for Tomorrows Hot OTC Market Leaders Today!Email:
Sign up at OTC Volume leaders and get access to info on hundreds of the most active OTCBB companies by clicking the sign up link below
http://bit.ly/otcvolumeleaders
OTC/Market Commentary:
Sectors include Biotech Stocks
One of the OTCBB volume leader reports; Soligenix, Inc. (OTCBB: SNGX): "Soligenix, Inc. (Soligenix) is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. Soligenix's lead product, orBec® (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of acute gastrointestinal Graft-versus-Host-Disease (GI GVHD), a common and potentially life-threatening complication of hematopoietic cell transplantation. orBec® is currently the subject of a confirmatory Phase 3 clinical trial for the treatment of acute GI GVHD and an NIH-supported, Phase 2, randomized, double-blind, placebo-controlled trial in the prevention of acute GVHD. Soligenix is also conducting an NIH-supported Phase 1/2 clinical trial of SGX201 in the prevention of acute radiation enteritis. Additionally, Soligenix has a Lipid Polymer Micelle (LPM™) drug delivery technology for the oral delivery of leuprolide for the treatment of prostate cancer and endometriosis.
Through its Biodefense Division, Soligenix is developing biomedical countermeasures pursuant to the Project BioShield Act of 2004. Soligenix's lead biodefense product in development is a recombinant subunit vaccine called RiVax™, which is designed to protect against the lethal effects of exposure to ricin toxin. RiVax™ has been shown to be well tolerated and immunogenic in a Phase 1 clinical trial in normal volunteers. RiVax™ is also the subject of a $9.4 million NIH grant received by the Company supporting development of new heat stable vaccines.
For further information regarding Soligenix, Inc., please visit the Company's website at http://www.soligenix.com/."
Market Snapshot: (at time of release)
Dow 10,851.74 +39.70 +0.37%
Nasdaq 2,374.76 +4.99 +0.21%
S&P 500 1,145.65 +3.49 +0.31%
10 Yr Bond(%) 2.4800% -0.3700
Oil 76.76 +0.24 +0.31%
Gold 1,287.50 -3.40 -0.26%
OTCBB Investors: Take the few minutes to register with us at To sign up for free Newsletter http://bit.ly/otcvolumeleaders and get access to info on hundreds of the most active OTCBB companies and keep up to date with developments of the companies.
OTC VOLUME LEADERS provides investors with daily market updates showcasing the most actively traded OTCBB Companies. We strive to provide you with the most up-to-date market information and activity by searching through hundreds of OTCBB companies in order to provide you information on the best of these companies. The goal is to continually find tomorrow’s market leading companies, today!
OTCVolumeleaders.com has not been compensated by any of the above mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks.
Please view the full disclaimer: http://www.otcvolumeleaders.com/Source http://www.otcvolumeleaders.com/Follow OTC Volume Leaders on Twitter.com http://twitter.com/OTCVolumeLeader
* Attention Investors in British Columbia Canada: Do not subscribe to any OTC stocks not currently filing with Sedar in BC and BC Securities
Visit the OTC showcase profile at Investorideas.com Request News and Info on OTC Investors - Get OTC stock quotes from http://www.otcmarkets.com/ Disclosure, Disclaimer/ OTC is a paid advertising client on Investorideas.com.
More Info:
Published at http://www.investorideas.com/ - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Monday, September 27, 2010
Investorideas.com - Biotech Stocks on the Move: High Volume Traders; (OTCBB: UVFT), (OTCBB: KBLB), (NASDAQ:SGEN), (NASDAQ:GENZ)
Investorideas.com - Biotech Stocks on the Move: High Volume Traders; (OTCBB: UVFT), (OTCBB: KBLB), (NASDAQ:SGEN), (NASDAQ:GENZ)
Category: Investment, Biotech
Subscribe to Investor Ideas Newswire
Visit this company: www.uvflutech.com
Point Roberts, WA - September 27, 2010 (Investorideas.com Newswire, www.biotechindustrystocks.com) - InvestorIdeas.com, a leader in sector research for investors, reports on recent Volume Leading Biotech/ Pharma Stocks news and trading for September 27th on the OTCBB and NASDAQ Markets. Top gainers included Seattle Genetics, Inc. (NASDAQ: SGEN), one of the most advanced stocks on the Nasdaq.com in morning trading.
Biotech Stocks include UV Flu Technologies, Inc., (OTCBB: UVFT), Seattle Genetics Inc (NASDAQ:SGEN), Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB), and Genzyme Corp. (NASDAQ:GENZ)
Sector Snapshot: (Trading at time or release)
UV Flu Technologies, Inc., (OTCBB: UVFT) trading at $ 0.34, up 0.02 (6.25%)
Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB), trading at $ 0. 2410, up 0.0229 (10.04%) on Volume of 13,387,394 shares
Seattle Genetics Inc. (NASDAQ: SGEN), trading at $14.91, up 2.75 (22.62%) on Volume of 7,333,439 shares
Genzyme Corp. (NASDAQ:GENZ) trading at $ 71.75, up 0.15 (0.21%)
Biotech Stocks to Watch; Recent News
UV Flu Technologies, Inc., (OTCBB: UVFT) Key Highlights and Recent Press
UV Flu Technologies, Inc., (OTCBB: UVFT) is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector. The Company manufactures the VIRATECH UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. UV Flu is committed to providing clean air to improve health and prevent the spread of disease.
The company recently announced that in response to recent outbreaks of drug resistant superbugs such as NDM-1, and persistent occurrences of highly contagious strains of bacteria such as MRSA, the Company is implementing a national campaign to inform the public how its ViraTech UV-400 indoor air purifier significantly helps reduce exposure risks.
UV Flu Technologies, Inc., Key Highlights
FDA Approved as a Class II Medical device
Extensive testing by EPA and FDA certified laboratories confirm the proprietary system has over 99% effectiveness of eliminating bacteria
The Company's strategic differentiators include excellent independent test results proving the effectiveness and safety of its products, proprietary design, and FDA market clearance approving the sale of its products as medical devices.
The Company has been issued U.S. Patent No. 6939397 with 43 claims covering its innovative removable cartridge, housing, UV chamber, UV radiation source and baffle technology.
UV Flu's products are environmentally friendly. The energy efficient system does not use or produce ozone, uses less energy than a 100 watt light bulb and can qualify for Green Building programs.
Experts have warned that a new type of drug-resistant superbug is emerging. NDM-1 is a gene carried by bacteria that makes the strain resistant to some of the most powerful antibiotics. NDM-1 can easily now jump from one strain of bacteria to another.
Latest News:
"UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") is pleased to announce that the company and its flagship UV-400 air purification system will be featured on a segment of the “Designing Spaces” TV Show, to be aired nationally during the 4th quarter. The show, to be aired on the Women’s Entertainment channel, is scheduled for the holiday season and is expected to reach up to 75 million households."
Full Article: http://finance.yahoo.com/news/UV-Flu-Technologies-to-Be-iw-1288158894.html?x=0&.v=1
Website: http://www.uvflutech.com/
Seattle Genetics Inc (NASDAQ:SGEN)
Seattle Genetics Inc (NASDAQ:SGEN) Recent News: “Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502 - News), today announced positive top-line results from the pivotal trial of single-agent brentuximab vedotin (SGN-35), an antibody-drug conjugate (ADC) targeted to CD30. The trial was conducted in 102 relapsed or refractory Hodgkin lymphoma (HL) patients.
Seventy-five percent of patients in the pivotal trial achieved an objective response as assessed by an independent central review, the primary endpoint of the trial. The median duration of response was greater than six months. The safety profile of brentuximab vedotin in this trial was generally consistent with prior clinical trial experience. A more complete data set will be presented at an upcoming scientific meeting."
Full News http://www.investorideas.com/news/9273.asp
About Seattle Genetics Inc (NASDAQ:SGEN):
Seattle Genetics is a clinical-stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. The company’s lead product candidate, brentuximab vedotin, is being evaluated in a variety of lymphoma treatment settings including the relapsed and refractory Hodgkin lymphoma indication for which top-line pivotal data have been reported. In addition, Seattle Genetics has four other clinical-stage programs: SGN-75, ASG-5ME, dacetuzumab (SGN-40) and SGN-70. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Bayer, Celldex Therapeutics, Daiichi Sankyo, Genentech, GlaxoSmithKline, MedImmune, a subsidiary of AstraZeneca, Millennium: The Takeda Oncology Company and Progenics, as well as ADC co-development agreements with Agensys, an affiliate of Astellas, and Genmab. More information can be found at www.seattlegenetics.com.
Market Snapshot: (at time of release)
Dow 10,832.48 -27.78 -0.26% Nasdaq 2,372.96 -8.26 -0.35% S&P 500 1,144.53 -4.14 -0.36% 10 Yr Bond (%) 2.5300% -0.8200 Oil 75.68 -0.81 -1.06% Gold 1,297.00 +1.00 +0.08%
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About our Biotech investor portal:
BiotechIndustryStocks.com Portal is a global meeting place for investors and industry following the sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
Disclaimer: The following news is paid for by third party on behalf of UV Flu Technologies, Inc., (eight hundred) Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
C Van Zant: 800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com
Category: Investment, Biotech
Subscribe to Investor Ideas Newswire
Visit this company: www.uvflutech.com
Point Roberts, WA - September 27, 2010 (Investorideas.com Newswire, www.biotechindustrystocks.com) - InvestorIdeas.com, a leader in sector research for investors, reports on recent Volume Leading Biotech/ Pharma Stocks news and trading for September 27th on the OTCBB and NASDAQ Markets. Top gainers included Seattle Genetics, Inc. (NASDAQ: SGEN), one of the most advanced stocks on the Nasdaq.com in morning trading.
Biotech Stocks include UV Flu Technologies, Inc., (OTCBB: UVFT), Seattle Genetics Inc (NASDAQ:SGEN), Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB), and Genzyme Corp. (NASDAQ:GENZ)
Sector Snapshot: (Trading at time or release)
UV Flu Technologies, Inc., (OTCBB: UVFT) trading at $ 0.34, up 0.02 (6.25%)
Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB), trading at $ 0. 2410, up 0.0229 (10.04%) on Volume of 13,387,394 shares
Seattle Genetics Inc. (NASDAQ: SGEN), trading at $14.91, up 2.75 (22.62%) on Volume of 7,333,439 shares
Genzyme Corp. (NASDAQ:GENZ) trading at $ 71.75, up 0.15 (0.21%)
Biotech Stocks to Watch; Recent News
UV Flu Technologies, Inc., (OTCBB: UVFT) Key Highlights and Recent Press
UV Flu Technologies, Inc., (OTCBB: UVFT) is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector. The Company manufactures the VIRATECH UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. UV Flu is committed to providing clean air to improve health and prevent the spread of disease.
The company recently announced that in response to recent outbreaks of drug resistant superbugs such as NDM-1, and persistent occurrences of highly contagious strains of bacteria such as MRSA, the Company is implementing a national campaign to inform the public how its ViraTech UV-400 indoor air purifier significantly helps reduce exposure risks.
UV Flu Technologies, Inc., Key Highlights
FDA Approved as a Class II Medical device
Extensive testing by EPA and FDA certified laboratories confirm the proprietary system has over 99% effectiveness of eliminating bacteria
The Company's strategic differentiators include excellent independent test results proving the effectiveness and safety of its products, proprietary design, and FDA market clearance approving the sale of its products as medical devices.
The Company has been issued U.S. Patent No. 6939397 with 43 claims covering its innovative removable cartridge, housing, UV chamber, UV radiation source and baffle technology.
UV Flu's products are environmentally friendly. The energy efficient system does not use or produce ozone, uses less energy than a 100 watt light bulb and can qualify for Green Building programs.
Experts have warned that a new type of drug-resistant superbug is emerging. NDM-1 is a gene carried by bacteria that makes the strain resistant to some of the most powerful antibiotics. NDM-1 can easily now jump from one strain of bacteria to another.
Latest News:
"UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") is pleased to announce that the company and its flagship UV-400 air purification system will be featured on a segment of the “Designing Spaces” TV Show, to be aired nationally during the 4th quarter. The show, to be aired on the Women’s Entertainment channel, is scheduled for the holiday season and is expected to reach up to 75 million households."
Full Article: http://finance.yahoo.com/news/UV-Flu-Technologies-to-Be-iw-1288158894.html?x=0&.v=1
Website: http://www.uvflutech.com/
Seattle Genetics Inc (NASDAQ:SGEN)
Seattle Genetics Inc (NASDAQ:SGEN) Recent News: “Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502 - News), today announced positive top-line results from the pivotal trial of single-agent brentuximab vedotin (SGN-35), an antibody-drug conjugate (ADC) targeted to CD30. The trial was conducted in 102 relapsed or refractory Hodgkin lymphoma (HL) patients.
Seventy-five percent of patients in the pivotal trial achieved an objective response as assessed by an independent central review, the primary endpoint of the trial. The median duration of response was greater than six months. The safety profile of brentuximab vedotin in this trial was generally consistent with prior clinical trial experience. A more complete data set will be presented at an upcoming scientific meeting."
Full News http://www.investorideas.com/news/9273.asp
About Seattle Genetics Inc (NASDAQ:SGEN):
Seattle Genetics is a clinical-stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. The company’s lead product candidate, brentuximab vedotin, is being evaluated in a variety of lymphoma treatment settings including the relapsed and refractory Hodgkin lymphoma indication for which top-line pivotal data have been reported. In addition, Seattle Genetics has four other clinical-stage programs: SGN-75, ASG-5ME, dacetuzumab (SGN-40) and SGN-70. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Bayer, Celldex Therapeutics, Daiichi Sankyo, Genentech, GlaxoSmithKline, MedImmune, a subsidiary of AstraZeneca, Millennium: The Takeda Oncology Company and Progenics, as well as ADC co-development agreements with Agensys, an affiliate of Astellas, and Genmab. More information can be found at www.seattlegenetics.com.
Market Snapshot: (at time of release)
Dow 10,832.48 -27.78 -0.26% Nasdaq 2,372.96 -8.26 -0.35% S&P 500 1,144.53 -4.14 -0.36% 10 Yr Bond (%) 2.5300% -0.8200 Oil 75.68 -0.81 -1.06% Gold 1,297.00 +1.00 +0.08%
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About our Biotech investor portal:
BiotechIndustryStocks.com Portal is a global meeting place for investors and industry following the sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
Disclaimer: The following news is paid for by third party on behalf of UV Flu Technologies, Inc., (eight hundred) Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
C Van Zant: 800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com
Subscribe to:
Posts (Atom)